Rapid genetic disorder test Xpert®

for leukemiafor BCR-ABL mutationsfor BCR-ABL

Each year, 1.9 newly diagnosed Chronic Myelogenous Leukaemia (CML) patients are identified per 100,000 individuals.1 CML prevalence is estimated to increase at an annual rate of 4%, and the number of individuals living with this disease will double by 2030.2 Managing CML in most diagnosed patients is achieved by oral administration of a Tyrosine Kinase Inhibitor (TKI) that specifically targets the activity of the BCR-ABL fusion protein. Currently, assessing treatment efficacy for CML requires a molecular diagnostic assay to measure the level of BCR-ABL transcript (RNA). Patients are tested for BCR-ABL every 3 months according to established international guidelines.3,4 Quantitative results are first normalized against a reference gene such as ABL.5 Subsequently, results are converted to an International Scale (IS) that harmonizes reporting of the molecular response.6 Despite efforts to optimise disease management, only one-third of newly diagnosed CML patients are adequately monitored during the first year of treatment.7 Therefore, more accessible molecular testing is needed for CML patient outcomes to improve. The Solution Xpert BCR-ABL Ultra is a quantitative test for BCR-ABL major breakpoint (p210) transcripts that provides highly sensitive and on-demand molecular results. Based on the innovative GeneXpert technology, Xpert BCR-ABL Ultra automates the entire test process including RNA isolation, reverse transcription, and fully nested real-time PCR of BCR-ABL target gene and ABL reference gene in one fully automated cartridge.,Benefits: Simply add the treated blood sample and an off-board reagent to the Xpert cartridge